Damaira Pharmaceuticals Pvt Ltd
About Damaira Pharmaceuticals Pvt Ltd
Certifications
Categories
-
IN
-
2023On CPHI since
-
2Certificates
-
100 - 249Employees
Company types
Primary activities
Meet us at
CPHI & PMEC India 2024
India Expo Centre, Greater Noida, Delhi NCR
26 Nov 2024 - 28 Nov 2024
CPHI Frankfurt 2025
Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
Products from Damaira Pharmaceuticals Pvt Ltd (6)
-
Product Meropenem 500 mg Powder for Injection
Meropenem is indicated for all age group including infants above 3 months of age as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: Pneumonias and Nosocomial Pneumonias Urinary Tract Infections Intra-abdominal Infect... -
Product Biapenem
Biapenem is a trusted broad - spectrum antibiotic for healthcare professionals with proven clinical effectiveness.it is well - suited therapy for various infections, including those caused by multidrug - resistant bacteria. it ensures optimal patient care and successful treatment outcomes. -
Product Doripenem
Doripenem is an exceptional antibiotic which is effective against complicated infections which offers broad - spectrum coverage and reliable treatment outcomes.
Doripenem is an indispensable tool for healthcare providers that combat a wide array of infectious diseases. -
Product Ertapenem
Ertapenem is versatile antibiotic with the advantage of once - daily dosing and broad - spectrum coverage. it is widely used for various infections, especially for surgical and hospital - acquired infections. it is an essential part of modern healthcare, that ensures the best possible outcomes. -
Product Imipenem Cilastatin
Imipenem Cilastatin is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below
Lower respiratory tract infectionsUrinary tract infections (complicated and uncomplicated)Intra-abdominal infec... -
Product Meropenem
Meropenem is indicated for all age group including infants above 3 months of age as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms:
Pneumonias and Nosocomial PneumoniasUrinary Tract InfectionsIntra-abdominal...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance